TISIDB

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus.
Domain	PF00010 Helix-loop-helix DNA-binding domain PF01056 Myc amino-terminal region
Function	Positively regulates the transcription of MYCNOS in neuroblastoma cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001502 cartilage condensation GO:0001763 morphogenesis of a branching structure GO:0002053 positive regulation of mesenchymal cell proliferation GO:0002065 columnar/cuboidal epithelial cell differentiation GO:0007423 sensory organ development GO:0008544 epidermis development GO:0009913 epidermal cell differentiation GO:0010001 glial cell differentiation GO:0010463 mesenchymal cell proliferation GO:0010464 regulation of mesenchymal cell proliferation GO:0010721 negative regulation of cell development GO:0014013 regulation of gliogenesis GO:0014014 negative regulation of gliogenesis GO:0030323 respiratory tube development GO:0030324 lung development GO:0030326 embryonic limb morphogenesis GO:0030856 regulation of epithelial cell differentiation GO:0035107 appendage morphogenesis GO:0035108 limb morphogenesis GO:0035113 embryonic appendage morphogenesis GO:0035239 tube morphogenesis GO:0035315 hair cell differentiation GO:0042063 gliogenesis GO:0042490 mechanoreceptor differentiation GO:0042491 auditory receptor cell differentiation GO:0042733 embryonic digit morphogenesis GO:0043583 ear development GO:0045604 regulation of epidermal cell differentiation GO:0045607 regulation of auditory receptor cell differentiation GO:0045631 regulation of mechanoreceptor differentiation GO:0045682 regulation of epidermis development GO:0045685 regulation of glial cell differentiation GO:0045686 negative regulation of glial cell differentiation GO:0048562 embryonic organ morphogenesis GO:0048568 embryonic organ development GO:0048704 embryonic skeletal system morphogenesis GO:0048705 skeletal system morphogenesis GO:0048706 embryonic skeletal system development GO:0048708 astrocyte differentiation GO:0048710 regulation of astrocyte differentiation GO:0048712 negative regulation of astrocyte differentiation GO:0048736 appendage development GO:0048754 branching morphogenesis of an epithelial tube GO:0048839 inner ear development GO:0050768 negative regulation of neurogenesis GO:0051216 cartilage development GO:0051961 negative regulation of nervous system development GO:0060113 inner ear receptor cell differentiation GO:0060173 limb development GO:0060541 respiratory system development GO:0060562 epithelial tube morphogenesis GO:0060563 neuroepithelial cell differentiation GO:0061138 morphogenesis of a branching epithelium GO:0061448 connective tissue development GO:0072593 reactive oxygen species metabolic process GO:0098743 cell aggregation GO:2000377 regulation of reactive oxygen species metabolic process GO:2000378 negative regulation of reactive oxygen species metabolic process GO:2000980 regulation of inner ear receptor cell differentiation
Molecular Function	-
Cellular Component	GO:0000785 chromatin

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MYCN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MYCN and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
17710228	Neuroblastoma	Inhibit immunity (infiltration)	Here, we report that the v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN), the hallmark of aggressive neuroblastoma, repressed expression of monocyte chemoattractant protein-1/CC chemokine ligand 2 (MCP-1/CCL2), a chemokine required for NKT cell chemoattraction. MYCN knockdown in MYCN-amplified neuroblastoma cell lines restored CCL2 production and NKT cell chemoattraction. MYCN overexpression in neuroblastoma xenografts in NOD/SCID mice severely inhibited their ability to attract human NKT cells, T cells, and monocytes. Patients with MYCN-amplified neuroblastoma metastatic to bone marrow had 4-fold fewer NKT cells in their bone marrow than did their nonamplified counterparts, indicating that the MYCN-mediated immune escape mechanism, which we believe to be novel, is operative in metastatic cancer and should be considered in tumor immunobiology and for the development of new therapeutic strategies.
29632319	neuroblastoma	Inhibit immunity	In this review, we will summarize and discuss the latest progress in the study of TNFR2-targeting pharmacological agents and their therapeutic potential based on upregulation or downregulation of Treg activity.

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MYCN in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MYCN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.017	0.974
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.21	0.803
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.123	0.864
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1.096	0.273
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.521	0.708
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.841	0.28
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.321	0.67
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.838	0.438
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.257	0.822
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.153	0.794
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.478	0.537
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.218	0.512

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MYCN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	20	0	20	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYCN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYCN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYCN. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYCN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MYCN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MYCN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MYCN
Name	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases	bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location	2p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MYCN collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MYCN